{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:57:44Z","timestamp":1790197064215,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00404-019-05139-3","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T13:06:42Z","timestamp":1554210402000},"page":"1737-1746","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Blockade pf CD73\/adenosine axis improves the therapeutic efficacy of docetaxel in epithelial ovarian cancer"],"prefix":"10.1007","volume":"299","author":[{"given":"Hongmei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihua","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohua","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6006-7205","authenticated-orcid":false,"given":"Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"issue":"1","key":"5139_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7\u201330. \n                    https:\/\/doi.org\/10.3322\/caac.21387","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"5139_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","volume":"14","author":"BM Reid","year":"2017","unstructured":"Reid BM, Permuth JB, Sellers TA (2017) Epidemiology of ovarian cancer: a review. Cancer Biol Med 14(1):9\u201332. \n                    https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2016.0084","journal-title":"Cancer Biol Med"},{"issue":"1","key":"5139_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5528\/wjtm.v3.i1.1","volume":"3","author":"A Desai","year":"2014","unstructured":"Desai A, Xu J, Aysola K, Qin Y, Okoli C, Hariprasad R, Chinemerem U, Gates C, Reddy A, Danner O, Franklin G, Ngozi A, Cantuaria G, Singh K, Grizzle W, Landen C, Partridge EE, Rice VM, Reddy ES, Rao VN (2014) Epithelial ovarian cancer: an overview. World J Transl Med 3(1):1\u20138. \n                    https:\/\/doi.org\/10.5528\/wjtm.v3.i1.1","journal-title":"World J Transl Med"},{"issue":"6","key":"5139_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.clon.2005.05.009","volume":"17","author":"AE Guppy","year":"2005","unstructured":"Guppy AE, Nathan PD, Rustin GJ (2005) Epithelial ovarian cancer: a review of current management. Clin Oncol (Royal College of Radiologists (Great Britain)) 17(6):399\u2013411","journal-title":"Clin Oncol (Royal College of Radiologists (Great Britain))"},{"key":"5139_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2147\/IJWH.S52379","volume":"7","author":"JI Coward","year":"2015","unstructured":"Coward JI, Middleton K, Murphy F (2015) New perspectives on targeted therapy in ovarian cancer. Int J Womens Health 7:189\u2013203. \n                    https:\/\/doi.org\/10.2147\/ijwh.s52379","journal-title":"Int J Womens Health"},{"key":"5139_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1756-9966-31-14","volume":"31","author":"A Kim","year":"2012","unstructured":"Kim A, Ueda Y, Naka T, Enomoto T (2012) Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res CR 31:14. \n                    https:\/\/doi.org\/10.1186\/1756-9966-31-14","journal-title":"J Exp Clin Cancer Res CR"},{"key":"5139_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17071169","author":"G Mittica","year":"2016","unstructured":"Mittica G, Genta S, Aglietta M, Valabrega G (2016) Immune checkpoint inhibitors: a new opportunity in the treatment of ovarian cancer? Int J Mol Sci. \n                    https:\/\/doi.org\/10.3390\/ijms17071169","journal-title":"Int J Mol Sci"},{"issue":"9","key":"5139_CR8","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/jnci\/87.9.676","volume":"87","author":"MJ Piccart","year":"1995","unstructured":"Piccart MJ, Gore M, Ten Bokkel Huinink W, Van Oosterom A, Verweij J, Wanders J, Franklin H, Bayssas M, Kaye S (1995) Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87(9):676\u2013681","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"5139_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/1758834010361333","volume":"2","author":"M Cristea","year":"2010","unstructured":"Cristea M, Han E, Salmon L, Morgan RJ (2010) Practical considerations in ovarian cancer chemotherapy. Ther Adv Med Oncol 2(3):175\u2013187. \n                    https:\/\/doi.org\/10.1177\/1758834010361333","journal-title":"Ther Adv Med Oncol"},{"issue":"Suppl 3","key":"5139_CR10","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1038\/sj.bjc.6601495","volume":"89","author":"N Katsumata","year":"2003","unstructured":"Katsumata N (2003) Docetaxel: an alternative taxane in ovarian cancer. Br J Cancer 89(Suppl 3):S9\u2013s15. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6601495","journal-title":"Br J Cancer"},{"issue":"4","key":"5139_CR11","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1091\/mbc.10.4.947","volume":"10","author":"AM Yvon","year":"1999","unstructured":"Yvon AM, Wadsworth P, Jordan MA (1999) Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 10(4):947\u2013959. \n                    https:\/\/doi.org\/10.1091\/mbc.10.4.947","journal-title":"Mol Biol Cell"},{"issue":"17","key":"5139_CR12","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.2165\/00003495-200565170-00007","volume":"65","author":"KA Lyseng-Williamson","year":"2005","unstructured":"Lyseng-Williamson KA, Fenton C (2005) Docetaxel: a review of its use in metastatic breast cancer. Drugs 65(17):2513\u20132531. \n                    https:\/\/doi.org\/10.2165\/00003495-200565170-00007","journal-title":"Drugs"},{"issue":"3","key":"5139_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.immuni.2018.03.004","volume":"48","author":"MD Wellenstein","year":"2018","unstructured":"Wellenstein MD, de Visser KE (2018) Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity 48(3):399\u2013416. \n                    https:\/\/doi.org\/10.1016\/j.immuni.2018.03.004","journal-title":"Immunity"},{"issue":"3","key":"5139_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","volume":"31","author":"KG Anderson","year":"2017","unstructured":"Anderson KG, Stromnes IM, Greenberg PD (2017) Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell 31(3):311\u2013325. \n                    https:\/\/doi.org\/10.1016\/j.ccell.2017.02.008","journal-title":"Cancer Cell"},{"issue":"2","key":"5139_CR15","doi-asserted-by":"publisher","first-page":"e89350","DOI":"10.1371\/journal.pone.0089350","volume":"9","author":"Z Guo","year":"2014","unstructured":"Guo Z, Wang X, Cheng D, Xia Z, Luan M, Zhang S (2014) PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS ONE 9(2):e89350. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0089350","journal-title":"PLoS ONE"},{"issue":"9","key":"5139_CR16","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.4161\/hv.20738","volume":"8","author":"GM Mantia-Smaldone","year":"2012","unstructured":"Mantia-Smaldone GM, Corr B, Chu CS (2012) Immunotherapy in ovarian cancer. Hum Vaccines Immunother 8(9):1179\u20131191. \n                    https:\/\/doi.org\/10.4161\/hv.20738","journal-title":"Hum Vaccines Immunother"},{"key":"5139_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10080242","author":"GM Rodriguez","year":"2018","unstructured":"Rodriguez GM, Galpin KJC, McCloskey CW, Vanderhyden BC (2018) The tumor microenvironment of epithelial ovarian cancer and its influence on response to immunotherapy. Cancers. \n                    https:\/\/doi.org\/10.3390\/cancers10080242","journal-title":"Cancers"},{"issue":"9","key":"5139_CR18","doi-asserted-by":"publisher","first-page":"e1216292","DOI":"10.1080\/2162402X.2016.1216292","volume":"5","author":"L Antonioli","year":"2016","unstructured":"Antonioli L, Blandizzi C, Malavasi F, Ferrari D, Hasko G (2016) Anti-CD73 immunotherapy: a viable way to reprogram the tumor microenvironment. Oncoimmunology 5(9):e1216292. \n                    https:\/\/doi.org\/10.1080\/2162402x.2016.1216292","journal-title":"Oncoimmunology"},{"issue":"1","key":"5139_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40425-018-0360-8","volume":"6","author":"RD Leone","year":"2018","unstructured":"Leone RD, Emens LA (2018) Targeting adenosine for cancer immunotherapy. J Immunother Cancer 6(1):57. \n                    https:\/\/doi.org\/10.1186\/s40425-018-0360-8","journal-title":"J Immunother Cancer"},{"issue":"16","key":"5139_CR20","doi-asserted-by":"publisher","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-10-1544","volume":"70","author":"B Zhang","year":"2010","unstructured":"Zhang B (2010) CD73: a novel target for cancer immunotherapy. Can Res 70(16):6407\u20136411. \n                    https:\/\/doi.org\/10.1158\/0008-5472.can-10-1544","journal-title":"Can Res"},{"issue":"3","key":"5139_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","volume":"30","author":"A Young","year":"2016","unstructured":"Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, Huang Q, Liu J, Takeda K, Teng MWL, Sachsenmeier K, Smyth MJ (2016) Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell 30(3):391\u2013403. \n                    https:\/\/doi.org\/10.1016\/j.ccell.2016.06.025","journal-title":"Cancer Cell"},{"issue":"6","key":"5139_CR22","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1158\/0008-5472.CAN-09-3109","volume":"70","author":"D Jin","year":"2010","unstructured":"Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, Shin T, Curiel TJ, Zhang B (2010) CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Can Res 70(6):2245\u20132255. \n                    https:\/\/doi.org\/10.1158\/0008-5472.can-09-3109","journal-title":"Can Res"},{"key":"5139_CR23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/978-1-62703-547-7_24","volume":"1049","author":"BL Theriault","year":"2013","unstructured":"Theriault BL, Portelance L, Mes-Masson AM, Nachtigal MW (2013) Establishment of primary cultures from ovarian tumor tissue and ascites fluid. Methods Mol Biol (Clifton, NJ) 1049:323\u2013336. \n                    https:\/\/doi.org\/10.1007\/978-1-62703-547-7_24","journal-title":"Methods Mol Biol (Clifton, NJ)"},{"issue":"130","key":"5139_CR24","doi-asserted-by":"publisher","first-page":"130ra148","DOI":"10.1126\/scitranslmed.3003601","volume":"4","author":"YD Yao","year":"2012","unstructured":"Yao YD, Sun TM, Huang SY, Dou S, Lin L, Chen JN, Ruan JB, Mao CQ, Yu FY, Zeng MS, Zang JY, Liu Q, Su FX, Zhang P, Lieberman J, Wang J, Song E (2012) Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci Transl Med 4(130):130ra148. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.3003601","journal-title":"Sci Transl Med"},{"issue":"46","key":"5139_CR25","doi-asserted-by":"publisher","first-page":"19997","DOI":"10.1073\/pnas.1009010107","volume":"107","author":"F Su","year":"2010","unstructured":"Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, Grijalva V, Ng C, Wagner A, Hough G, Farias-Eisner G, Anantharamaiah GM, Van Lenten BJ, Navab M, Fogelman AM, Reddy ST, Farias-Eisner R (2010) Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci USA 107(46):19997\u201320002. \n                    https:\/\/doi.org\/10.1073\/pnas.1009010107","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-019-05139-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-019-05139-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-019-05139-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T23:19:53Z","timestamp":1585696793000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-019-05139-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["5139"],"URL":"https:\/\/doi.org\/10.1007\/s00404-019-05139-3","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,2]]},"assertion":[{"value":"17 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Human study was approved by the Ethical Committee in Heze Municipal Hospital of Shandong Province. All animal studies were in accordance with Guide for the Care and Use of Laboratory Animals (8th edition, NIH), and approved by the Institutional Animal Care and Use Committee in Heze Municipal Hospital of Shandong Province.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Written consent was derived from the participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}